Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | HTR2B | P41595 | 7/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29301888 | 1.00 | HTR1A (0.43) | HTR1ASLC6A2PDE4BPDE4AHTR2C | |
| Hydrochloric Acid SCHEMBL6969650 | 0.99 | HTR1A (0.42) | HTR1ASLC6A2PDE4BPDE4AHTR2C | |
| Hydrochloric Acid SCHEMBL6963984 | 0.99 | HTR1A (0.42) | HTR1ASLC6A2PDE4BPDE4AHTR2C | |
| Hydrochloric Acid SCHEMBL6959004 | 0.99 | HTR1A (0.42) | HTR1ASLC6A2PDE4BPDE4AHTR2C | |
| SCHEMBL10199778 | 0.89 | PDE4A (0.40) | HTR1ASLC6A2PDE4AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6954720 | 0.88 | PDE4A (0.40) | PDE4AHTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL8554408 | 0.86 | PDE4A (0.40) | PDE4AHTR2CHTR2BHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL6964728 | 0.85 | ADRA1D (0.40) | PDE4AHTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL11626560 | 0.75 | ALDH1A1 (0.49) | HTR2CHTR2BHTR2A | |
| SCHEMBL8441694 | 0.73 | ESR1 (0.39) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| WO-2014195695-A1 | THERAPEUTIC COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-12-11 | — | — | WO | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| WO-2014144130-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC (US) | 2014-09-18 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023225492-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023220930-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS CROSS-REFERENCES TO RELATED APPLICATIONS | INCREVET, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | SATO PHARMACEUTICAL CO., LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-05-21 | — | — | US | disclosed |
| EP-2018863-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-01-28 | — | — | EP | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1792629-A1 | PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131402-A1 | Fused heterocyclic compound and use thereof | HTR2C, HTR3C, HTR3B | HTR1A 9/4885SLC6A2 36/4885PDE4B 778/4885 |
| US-20220249440-A1 | MUSCLE REGENERATION PROMOTER | MUSK, MYLK2, MYH2 | HTR1A 20/4885SLC6A2 430/4885PDE4B 191/4885 |
| US-20230372374-A1 | VETERINARY PHARMACEUTICAL FORMULATIONS | SLC5A2, SLC5A1, SLC2A8 | HTR1A 882/4885SLC6A2 221/4885PDE4B 470/4885 |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | HTR1A 11/4885SLC6A2 158/4885PDE4B 846/4885 |
| US-20070274913-A1 | Preventives/Remedies for Stress Urinary Incontinence and Method of Screening the Same | ADRA2C, HTR2C, HTR3A | HTR1A 9/4885SLC6A2 57/4885PDE4B 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.